Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Shares of Kenvue (KVUE) rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

ConocoPhillips CFO to retire after 39 years with the company, Kenvue and Mattel name new finance chiefs and Vodafone’s CFO to ...

Kenvue named Kellanova Chief Financial Officer Amit Banati to that role at the over-the-counter drug maker, replacing current financial chief Paul Ruh, effective May 12. Banati has worked in executive ...

Gordon Haskett reports that the judge overseeing the initial California Tylenol lawsuit against Kenvue (KVUE) granted summary ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

We expect Kenvue, with the freedom to allocate capital and invest as a stand-alone entity, to focus on its 15 priority brands (including Tylenol, Nicorette, Listerine, and Zyrtec) to drive future ...

Self care segment revenue growth updated Consumer health company Kenvue Inc. (NYSE:KVUE) on Thursday reported first-quarter ...

Kenvue KVUE4.11%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...

Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the ...